Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 27.95 PB Ratio: 2.13 GF Score: 53/100

Biogen Inc at Cowen Health Care Conference Transcript

Mar 11, 2019 / 03:20PM GMT
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

Good morning, and welcome once again to Cowen & Company's 39th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to introduce one of our first companies, Biogen, one of the luminaries in the industry. Then we're going to do a fireside chat with CEO, Michel Vounatsos.

Michel, do you want to start with maybe some opening remarks?

Michel Vounatsos
Biogen Inc. - CEO & Director

Certainly. So good morning, everybody. And thank you for having Biogen and me.

We may make some forward-looking statements, so I refer you back to our SEC filing.

2018 was a very good year. Top line double digit. Bottom line, even stronger. And I would say more importantly, we have enriched and advanced our pipeline portfolio very well, beyond aducanumab. But for aducanumab also, we increased the POS based on the results of BAN2401. And we are very encouraged by the results of our ASO SOD1 program,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot